Clin DermRCT
Immune checkpoint inhibition in locally advanced, recurrent, and metastatic cutaneous squamous cell carcinoma.
From the abstractDespite the biologic rationale for biomarker-guided treatment, tumor mutational burden and programmed death ligand 1 expression have not shown sufficiently consistent, predictable values for clinical selection. Active investigations into the efficacy of immune checkpoint inhibitors in advanced resectable and unresectable cSCC are rapidly shifting management, with evidence revealing promises of greater disease-free survival through neoadjuvant and adjuvant approaches.
Vromans AM, Harrop B, … senior author Hadfield MJClinics in Dermatology